Bliss GVS Pharma Limited

Anupam Rasayan is significantly expanding its pharmaceutical footprint through a series of acquisitions culminating in the planned purchase of a 74.2% stake in Bliss GVS Pharma for approximately ₹2,198.54 crore. This move, financed through a combination of debt and equity instruments, will create an integrated manufacturing platform spanning from key starting materials to finished formulations, broadening Anupam’s reach into regulated markets and enabling entry into the contract development and manufacturing organization (CDMO) space. The acquisition of Bliss GVS, which manufactures formulations across several therapeutic areas, represents a strategic backward integration for Anupam and is expected to be completed within six months, subject to regulatory approvals.